Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
TEVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.47 - $22.80
Previous CloseN/A
Volume1.13M
Average Volume (3M)11.98M
Market Cap
$20.84B
Enterprise Value$34.83B
Total Cash (Recent Filing)$2.16B
Total Debt (Recent Filing)$17.52B
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 06, 2025EPS Estimate
0.68Last Dividend Ex-Date
Nov 27, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)0.66
Shares Outstanding1,146,838,700
10 Day Avg. Volume10,642,614
30 Day Avg. Volume11,978,005
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)4.63
Price to Sales (P/S)1.51
P/FCF Ratio33.28
Enterprise Value/Market Cap1.67
Enterprise Value/Revenue2.09
Enterprise Value/Gross Profit4.22
Enterprise Value/Ebitda20.62
Forecast
1Y Price Target
$24.20Price Target Upside37.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGood execution on margin-side, notably GM and EBITDA margins increased significantly.
Market PositionTEVA is well-positioned for upside with shares trading at less than 7 times the 2025 estimated earnings per share and increasing capital allocation flexibility.
Product GrowthKey US brands Uzedy, Austedo, and Ajovy saw FY25 guidance raise of ~$100m, indicating strong growth potential.
Bears Say
Competitive PressureSpyre's TL1A antibodies have the potential to offer less frequent dosing compared to first-generation TL1As.
EarningsUS generics missed forecast, mainly due to lower g-Revlimid contribution.
Regulatory UncertaintyPending Austedo IRA pricing outcome has been a major stock overhang.
Teva Pharmaceutical News
TEVA FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was $12.46 and its highest was $22.80 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Teva Pharmaceutical’s market cap is $20.84B.
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is Nov 06, 2025 which is in 77 days.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on Jul 30, 2025. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.617 by $0.043.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.085 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is 0.68.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,146,838,700 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $0.66 in its last earnings report, beating expectations of $0.617. Following the earnings report the stock price went up 1.753%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Currently, no hedge funds are holding shares in TEVA
Teva Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Price Target Potential
57.35% Upside
Analyst Consensus
Strong Buy
Average Price Target:
$24.20 (37.81% Upside)
$24.20 (37.81% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.99%
12-Months-Change
Fundamentals
Return on Equity
-2.31%
Trailing 12-Months
Asset Growth
-2.92%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Company Deck
TEVA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive overall sentiment driven by strong growth in the innovative portfolio and strategic advancements in the pipeline, despite challenges in the generics market and uncertainties regarding tariffs.View all TEVA earnings summariesTEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
TEVA Stock 12 Month Forecast
Average Price Target
$24.20
▲(37.81% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Neurocrine
―
Perrigo Company
―
Elanco Animal Health
―
Ownership Overview
0.43% Insiders
7.53% Mutual Funds
19.82% Other Institutional Investors
68.63% Public Companies and Individual Investors